1. Soft Tissue and Bone Tumours WHO Classification of Tumours. 5th ed. IARC Publications; 2020.
Google Scholar2. Wehner, MS, Humphreys, JL, Sharkey, FE. Epididymal rhabdomyoma: report of a case, including histologic and immunohistochemical findings. Arch Pathol Lab Med. 2000; 124(10):1518–1519.
Google Scholar | Crossref | Medline3. Leite, KRM, Dantas, KOF, de Azevedo, LS, Camara-Lopes, LH. Paratesticular rhabdomyoma. Ann Diagn Pathol. 2006; 10(4):239–240.
Google Scholar | Crossref | Medline4. Morra, MN, Manson, AL, Gavrell, GJ, Quinn, AD. Rhabdomyoma of prostate. Urology. 1992; 39(3):271–273.
Google Scholar | Crossref | Medline5. Belyea, B, Kephart, JG, Blum, J, Kirsch, DG, Linardic, CM. Embryonic signaling pathways and rhabdomyosarcoma: contributions to cancer development and opportunities for therapeutic targeting. Sarcoma. 2012; 2012:406239.
Google Scholar | Crossref | Medline6. Butel, T, Karanian, M, Pierron, G, et al. Integrative clinical and biopathology analyses to understand the clinical heterogeneity of infantile rhabdomyosarcoma: a report from the French MMT committee. Cancer Med. 2020; 9(8):2698–2709.
Google Scholar | Crossref | Medline7. Gibas, Z, Miettinen, M. Recurrent parapharyngeal rhabdomyoma. Evidence of neoplastic nature of the tumor from cytogenetic study. Am J Surg Pathol. 1992; 16(7):721–728.
Google Scholar | Crossref | Medline8. Zhang, N, Zeng, Z, Li, S, Wang, F, Huang, P. High expression of EZH2 as a marker for the differential diagnosis of malignant and benign myogenic tumors. Sci Rep. 2018; 8(1):1–12.
Google Scholar | Medline9. Schoolmeester, JK, Xing, D, Keeney, GL, Sukov, WR. Genital rhabdomyoma of the lower female genital tract: a study of 12 cases with molecular cytogenetic findings. Int J Gynecol Pathol. 2018; 37(4):349–355.
Google Scholar | Crossref | Medline10. Robbins, KM, Stabley, DL, Holbrook, J, et al. Paternal uniparental disomy with segmental loss of heterozygosity of chromosome 11 are hallmark characteristics of syndromic and sporadic embryonal rhabdomyosarcoma. Am J Med Genet Part A. 2016; 170(12):3197–3206.
Google Scholar | Crossref | Medline11. Fagan, Richard J DAK . COMPASS ascending: emerging clues regarding the roles of MLL3/KMT2C and MLL2/KMT2D proteins in cancer. Cancer Lett. 2019; 458:56–65.
Google Scholar | Crossref | Medline12. Ji, J, Navid, F, Hiemenz, MC, et al. HHS public access. Cancer Genet. 2019; 231:62–66.
Google Scholar | Crossref | Medline13. Elson, GC, Lelièvre, E, Guillet, C, et al. CLF associates with CLC to form a functional heteromeric ligand for the CNTF receptor complex. Nat Neurosci. 2000; 3(9):867–872.
Google Scholar | Crossref | Medline14. Castoria, G, Donato, M Di, Zazzo, E Di, et al. CRLF1-MYH9 interaction regulates proliferation and metastasis of papillary thyroid carcinoma through the ERK/ETV4 axis. Front Endocrinol. 2020; 1:535.
Google Scholar15. Yu, S-T, Zhong, Q, Chen, R-H, et al. CRLF1 promotes malignant phenotypes of papillary thyroid carcinoma by activating the MAPK/ERK and PI3K/AKT pathways. Cell Death Dis. 2018; 9(3):371.
Google Scholar | Crossref | Medline